A smarter way to hand out overdose reversal kits?

NCT ID NCT05886712

Ongoing Prevention Sponsor: RTI International Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests a strategy called SAIA-N, which uses coaching and data review to help syringe service programs in California distribute more naloxone, a medication that reverses opioid overdoses. About 31 programs will either use this strategy for a year or continue their usual approach. Researchers will compare how many people receive naloxone and whether the strategy is cost-effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Naloxone
What this could lead to: If effective, this strategy could help syringe service programs distribute more naloxone, potentially reducing opioid overdose deaths in high-risk communities.
What could go wrong: This is a small pilot study (31 programs) in one state, so results may not apply broadly. The strategy requires time and resources, and its cost-effectiveness is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMPLEMENTATION AS USUAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug Overdose poisoning

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMPLEMENTATION AS USUAL OVERDOSE

Contacts and locations

Locations

RTI International

Berkeley, California, 94704, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.